StudyRareStudyRare

Cobalamin A deficiency (cblA)

Log in to star

Last updated Nov 15, 2026

Log in to add personal notes on this page.

A 4-month-old becomes lethargic and breathes fast during a viral illness. Blood gas shows a high anion gap metabolic acidosis. Urine organic acids show a large amount of methylmalonic acid with methylcitrate; plasma total homocysteine and serum B12 are normal. After three daily intramuscular injections of hydroxocobalamin, mean urine methylmalonic acid falls by more than half.

  • Autosomal recessive; MMAA (4q31.21, metabolism of cobalamin associated A); biallelic loss-of-function variants
  • One of the cofactor causes of isolated methylmalonic acidemia, with cblB (MMAB) and the methylmalonic-acidemia-only variant of cblD (MMADHC); the others are deficiencies of the mutase itself (MMUT)
  • c.433C>T (p.Arg145Ter) is the most common pathogenic variant, about 43% of mutated alleles in one large series
  • Segmental maternal uniparental isodisomy of chromosome 4 has made a child homozygous for a variant carried by only one parent, so a homozygous result does not prove that both parents are carriers
  • The name is a complementation group: cblA was one of the first three cobalamin groups separated by fusing patient fibroblasts (see cobalamin transport and processing)

The MMAA protein is a mitochondrial GTPase needed to load adenosylcobalamin, the B12 coenzyme, onto methylmalonyl-CoA mutase. The adenosyltransferase, the MMAB protein, makes the coenzyme and hands it to the mutase; the MMAA protein is needed for it to be assembled into the enzyme. In cblA the mutase protein is intact but runs short of its coenzyme, so methylmalonyl-CoA cannot become succinyl-CoA and methylmalonic acid accumulates.

Two consequences follow from the position of the block:

As in every form of isolated methylmalonic acidemia, the kidney is injured over time by tubulointerstitial nephritis, thought to reflect secondary mitochondrial dysfunction rather than direct toxicity of methylmalonic acid.

adenosyltransferaseMMAB; mitochondrionMMAA protein loads it onto themutaseMMAAcobalamin A deficiencymethylmalonyl-CoA mutaseMMUT; with methylmalonyl-CoAmethylmalonic acidemiaprocessed cobalaminadenosylcobalaminmutase holoenzymesuccinyl-CoA
Excerpt from cobalamin transport and processing. See the full pathway.

Part of cobalamin transport and processing.

Mitochondrial adenosylcobalamin delivery, the step that arms methylmalonyl-CoA mutase.

cobalamin → adenosyltransferase (MMAB) → adenosylcobalamin → MMAA protein (the block; loads the coenzyme onto the mutase) → methylmalonyl-CoA mutase (MMUT): methylmalonyl-CoA → succinyl-CoA → Krebs cycle

  • Accumulates: methylmalonic acid in urine and plasma, with C3 (propionylcarnitine) on newborn screening and 2-methylcitrate; total homocysteine is normal.
  • Missing: adenosylcobalamin on the mutase, and with it succinyl-CoA from propionate.
  • Workbook: 4.J. Methylmalonic acidemia (MMA) & propionic acidemia (PA)
  • Onset in infancy in most: in an adult series, 78% began before age one (median 4 months), most with acute neurologic deterioration; about a third never presented acutely, which is why methylmalonic acid belongs in the workup of unexplained chronic renal failure, intellectual disability, or poor growth (very long-term outcomes in 23 patients with cblA type methylmalonic acidemia, 2022)
  • Metabolic crisis (ketoacidosis, sometimes hyperammonemia) is the usual way the diagnosis is made; a missed or late diagnosis can leave basal ganglia (globus pallidus) injury and a movement disorder
  • Better outcome than mut0 and cblB: in 83 patients followed for a median of 18 years, mut0 and cblB had earlier onset, more complications, more deaths, and higher urine methylmalonic acid than mut- and cblA (long-term outcome in methylmalonic acidurias, 2007); one of 20 cblA patients died, against about half of mut0 and cblB. In the 2021 registry, all 28 cblA patients survived, kidney function was better preserved, and neurologic complications were concentrated in the mut group
  • Chronic kidney disease is still a risk: mut0, cblB, and cblA all carry an increased risk of chronic kidney disease from tubulointerstitial nephritis (renal dysfunction in methylmalonic acidurias, 2013). In the adult series, 30% had renal failure, but only one of seven patients treated with B12 from the start, with moderate failure beginning at 38
  • Intellectual disability in 39% of the adult series, while 56.5% lived independently. Siblings treated from the newborn period had higher IQs than older siblings diagnosed after symptoms began
  • Arrhythmia and cardiomyopathy have been reported, as in other forms of isolated methylmalonic acidemia
  • Newborn screening: raised C3 (propionylcarnitine) and C3/C2 ratio, the same marker as other forms of methylmalonic acidemia and propionic acidemia. Second-tier methylmalonic acid, 2-methylcitrate, and total homocysteine on the dried blood spot separate isolated methylmalonic acidemia from propionic acidemia and the combined defects
  • Follow-up: raised plasma and urine methylmalonic acid, with 3-hydroxypropionate, 2-methylcitrate, and tiglylglycine on urine organic acids; normal total homocysteine and serum B12. Check the mother's B12 too, since maternal deficiency raises C3 in the infant
  • Molecular: biallelic MMAA variants, usually on a panel for isolated methylmalonic acidemia (MMUT, MMAA, MMAB, MMADHC, MCEE). Fibroblast studies (propionate incorporation, complementation) help when the molecular result is equivocal
  • Cobalamin responsiveness testing is recommended for every patient with suspected methylmalonic acidemia (guidelines for methylmalonic acidaemia and propionic acidaemia, first revision, 2021): metabolically stable and off hydroxocobalamin for at least a month; at least three baseline urine or plasma methylmalonic acid samples on different days, in the same fluid; 1 mg hydroxocobalamin intramuscularly on three consecutive days; samples every other day for 10 days. A mean fall of more than 50% is a response
  • A negative trial does not exclude cblA: 61% of the adult series were first classed as B12-unresponsive, yet every one of the 13 whose fibroblasts were tested responded in vitro

Per the methylmalonic and propionic acidemia guideline (first revision, 2021) and GeneReviews:

  • Hydroxocobalamin by intramuscular injection, the preferred form and route, dosed by metabolic response (1 mg from one to three times a week up to daily). Hydroxocobalamin is preferred over cyanocobalamin, which is ineffective in cblC
  • Natural protein limited to what metabolic control and growth allow, with enough calories to prevent catabolism. Responsive patients often need less: in the 2021 registry, 73% of cblA and 98% of mut patients followed a calculated diet, and 27% and 69% took amino acid supplements
  • Levocarnitine for secondary carnitine deficiency
  • Emergency letter and plan for illness, with early glucose-containing fluids to avert catabolism, as for any form of methylmalonic acidemia
  • Kidney surveillance: cystatin C or measured glomerular filtration rate, because creatinine is a late marker in patients with low muscle mass; nephrotoxic drugs avoided. Most of the roughly 20 people with methylmalonic acidemia who received a kidney transplant alone had the milder mut- or cblA forms
  • Pregnancy at risk: after prenatal diagnosis, B12 has been given to the mother when the fetus has a responsive form, especially cblA; the benefit is not yet established
  • Recurrence risk 25% for each pregnancy of carrier parents

cblA Answers, cblB Barely: cblA is the isolated methylmalonic acidemia that almost always answers to hydroxocobalamin; cblB responds only in a minority and usually behaves like mut0.

Reference Links